FDA: Modified dosing recommendations for Erythropoiesis-Stimulating Agents
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals of modified recommendations for more conservative dosing of erythropoiesis-stimulating agents ( ESAs ) in patients with chronic kidney disease (CKD) to improve the safe use of these drugs.